Project Grant R15CA301437
Award Date
6/19/25
Completion Date
5/31/28
Dollars Obligated
$416K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,060,460 to the University of Louisville to investigate a dual-targeting compound that may prevent doxorubicin-induced cardiotoxicity. The research aims to optimize the protective effects of this compound against cardiotoxicity in tumor-free and tumor-bearing mice, determine if it prevents cardiotoxicity by activating CXCR7/AMPK to prevent cardiac cell death and...
The National Cancer Institute (NCI) awarded a 5-year, $375,134 Project Grant under the Cancer Treatment Research (CFDA 93.395) federal grant program to the University of Colorado-Denver. The grant supports research to reduce off-target accumulation of chemotherapeutic nanomedicines and improve the efficacy of cancer chemotherapy. Key activities include characterizing the immune response that limits nanoparticle delivery to healthy tissues, and exploring the potential to use this response to...
The National Cancer Institute (NCI) awarded a $619,294 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the University of California, San Diego (UCSD) to develop slow-release CPMV (Cowpea Mosaic Virus)-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to formulate CPMV-laden slow-release devices, establish and tune the release rates, confirm the structural integrity and biological activity of the released CPMV, and...
This Project Grant award of $1,271,780.00 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to develop small molecule adaptors for programming a universal chimeric antigen receptor (CAR) T cell therapy. The key objectives are to: 1) Develop small molecule adaptors to target the universal CAR to multiple antigens, including tumor cells and immunosuppressive cells; 2) Enhance targeting specificity using chemical switches...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
The National Cancer Institute (NCI) awarded a $1,506,651 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Virginia Commonwealth University (VCU) on July 18, 2024. The project aims to evaluate a new agent called PEPDG278D for overcoming drug resistance in non-small cell lung cancer (NSCLC). PEPDG278D is a recombinant human protein that induces the degradation of the oncogenic drivers EGFR and HER2, which are frequently overexpressed or mutated in NSCLC. The project will assess...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,881 to Duke University to develop novel immunotherapies using optimized tumor cell-penetrating antibodies. The primary objective is to translate these tumor cell-penetrating antibodies, which have demonstrated the ability to neutralize common oncogenic mutations like KRASG12D and control tumor growth, into the clinic. The research aims to elucidate the mechanisms...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $547,945 to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The key objectives are to: Investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of immune checkpoint inhibitor-induced myocarditis. Comprehensively characterize the 3D localization and transcriptional...
The National Cancer Institute (NCI) awarded a $135,594 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University (Stanford University) to develop novel pharmacological approaches to rewire oncogenic gene expression and induce cancer cell death. The key objectives are to: 1) Develop small molecule chemical inducers of proximity (CIPs) that can target and kill aggressive leukemias driven by mixed-lineage leukemia (MLL) fusion oncogenes, and...